文章引用说明 更多>> (返回到该文章)

Kris, M.G., Johnson, B.E., Kwiatkowski, D.J., Iafrate, A.J., Wistuba, I.I., Aronson, S.L., et al. (2011) Identification of Driver Mutations in Tumor Specimens from 1,000 Pa-tients with Lung Adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology, 29, abstr CRA7506.

被以下文章引用:

• 标题: 分子靶向药物与肿瘤Molecular Targeted Drugs and Tumors

  作者: 夏君燕, 朱平, 伍学强

  关键字: 乳腺癌, 非小细胞肺癌, 结直肠癌, 血液肿瘤, 靶向治疗Breast Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Blood Tumor, Targeted Therapy

  期刊名称: 《World Journal of Cancer Research》, Vol.5 No.4, 2015-11-26

  摘要: 依据已知肿瘤发生中涉及的异常分子或基因，设计针对这些特定分子和基因靶点的药物，选择性杀伤肿瘤细胞，这种治疗方法称为肿瘤的分子靶向治疗。目前分子靶向药物用于治疗乳腺癌、非小细胞肺癌、结直肠癌以及淋巴瘤、白血病等恶性肿瘤已取得令人瞩目的疗效。针对现有的治疗恶性肿瘤的分子靶向药物的作一综述。 According to the abnormal molecules or genes involved in the occurrence of the tumor, the drugs targeting these specific molecules and gene targets are designed, which are targeted to the tumor cells. This method of treatment is known as the molecular targeted therapy of tumor. At present, molecular targeted agents are used to treat breast cancer, non-small cell lung cancer, colorectal cancer, lymphoma, leukemia and other malignant tumors. The curative effect of these malignant tumors has been improved significantly. Molecular targeted agents for the treatment of malignant tumors will be described in this review.